HC Wainwright Issues Optimistic Forecast for AVXL Earnings

Anavex Life Sciences Corp. (NASDAQ:AVXL) – Analysts at HC Wainwright boosted their Q1 2025 earnings estimates for Anavex Life Sciences in a research note issued to investors on Thursday, December 26th. HC Wainwright analyst R. Selvaraju now forecasts that the biotechnology company will post earnings of ($0.17) per share for the quarter, up from their previous estimate of ($0.19). HC Wainwright currently has a “Buy” rating and a $42.00 target price on the stock. The consensus estimate for Anavex Life Sciences’ current full-year earnings is ($0.55) per share. HC Wainwright also issued estimates for Anavex Life Sciences’ Q2 2025 earnings at ($0.18) EPS, Q3 2025 earnings at ($0.21) EPS and FY2025 earnings at ($0.73) EPS.

Anavex Life Sciences (NASDAQ:AVXL) last released its earnings results on Monday, December 23rd. The biotechnology company reported ($0.14) EPS for the quarter, topping analysts’ consensus estimates of ($0.17) by $0.03.

Separately, D. Boral Capital reaffirmed a “buy” rating and issued a $46.00 target price on shares of Anavex Life Sciences in a report on Monday, December 23rd.

Anavex Life Sciences Stock Performance

AVXL stock opened at $11.04 on Monday. Anavex Life Sciences has a fifty-two week low of $3.25 and a fifty-two week high of $14.44. The firm has a market capitalization of $936.37 million, a price-to-earnings ratio of -22.08 and a beta of 0.73. The company’s 50 day moving average price is $8.29 and its 200 day moving average price is $6.46.

Institutional Inflows and Outflows

A number of institutional investors have recently made changes to their positions in the business. Bank of New York Mellon Corp grew its position in shares of Anavex Life Sciences by 17.1% in the 2nd quarter. Bank of New York Mellon Corp now owns 280,556 shares of the biotechnology company’s stock valued at $1,184,000 after acquiring an additional 40,895 shares during the period. Rhumbline Advisers raised its holdings in shares of Anavex Life Sciences by 15.8% in the 2nd quarter. Rhumbline Advisers now owns 119,289 shares of the biotechnology company’s stock worth $503,000 after acquiring an additional 16,293 shares during the last quarter. Renaissance Technologies LLC boosted its position in Anavex Life Sciences by 483.8% in the second quarter. Renaissance Technologies LLC now owns 466,437 shares of the biotechnology company’s stock worth $1,968,000 after purchasing an additional 386,537 shares during the last quarter. Marshall Wace LLP purchased a new stake in shares of Anavex Life Sciences during the second quarter worth $166,000. Finally, Squarepoint Ops LLC bought a new stake in shares of Anavex Life Sciences during the 2nd quarter valued at about $191,000. 31.55% of the stock is owned by institutional investors.

About Anavex Life Sciences

Anavex Life Sciences Corp., a clinical stage biopharmaceutical company, engages in the development of therapeutics for the treatment of central nervous system diseases. Its lead product candidate is ANAVEX 2-73 for the treatment of Alzheimer's disease and Parkinson's disease, as well as other central nervous system diseases, including rare diseases, such as Rett syndrome, a rare severe neurological monogenic disorder; and infantile spasms, Fragile X syndrome, and Angelman syndrome.